P

Provention Bio Inc
F:2VB

Watchlist Manager
Provention Bio Inc
F:2VB
Watchlist
Price: 21.6 EUR -0.46%
Market Cap: 2B EUR

Relative Value

There is not enough data to reliably calculate the relative value of 2VB.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

2VB Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
159.8
Median 5Y
158.7
Industry
2.6
vs History
vs Industry
Median 3Y
-18.1
Median 5Y
-17.3
Industry
21.7
vs History
vs Industry
Median 3Y
-27.3
Median 5Y
-26.1
Industry
16.6
vs History
vs Industry
Median 3Y
-38.8
Median 5Y
-37.1
Industry
22.5
vs History
vs Industry
Median 3Y
16.9
Median 5Y
16.2
Industry
2.3
vs History
vs Industry
Median 3Y
148.9
Median 5Y
147.7
Industry
2.9
vs History
vs Industry
Median 3Y
185.8
Median 5Y
177.4
Industry
5.5
vs History
vs Industry
Median 3Y
-15.1
Median 5Y
-14.4
Industry
13.1
vs History
vs Industry
Median 3Y
-14.9
Median 5Y
-14.3
Industry
16.6
vs History
vs Industry
Median 3Y
-25.4
Median 5Y
-24.2
Industry
15.8
vs History
vs Industry
Median 3Y
-25.1
Median 5Y
-24
Industry
19.1
vs History
vs Industry
Median 3Y
29.5
Median 5Y
29.3
Industry
1.9

Multiples Across Competitors

2VB Competitors Multiples
Provention Bio Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Provention Bio Inc
F:2VB
1.9B EUR 170.8 -19.4 -16.2 -16.1
US
Eli Lilly and Co
NYSE:LLY
929B USD 15.6 50.5 33.9 36.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
481.1B USD 5.2 19.2 15.7 20.4
CH
Roche Holding AG
SIX:ROG
249.4B CHF 4 26.5 11.3 13.2
UK
AstraZeneca PLC
LSE:AZN
210.1B GBP 4.8 29.7 108 158.1
CH
Novartis AG
SIX:NOVN
203.5B CHF 4.5 17.5 11.1 14.4
US
Merck & Co Inc
NYSE:MRK
241B USD 3.8 12.7 9.1 10.7
DK
Novo Nordisk A/S
CSE:NOVO B
1.3T DKK 4.2 12.9 9 10.5
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
144B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
US
P
Provention Bio Inc
F:2VB
Average P/E: 22.9
Negative Multiple: -19.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
50.5
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.2
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.7
38%
0.8
CH
Novartis AG
SIX:NOVN
17.5
17%
1
US
Merck & Co Inc
NYSE:MRK
12.7
15%
0.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.9
4%
3.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
P
Provention Bio Inc
F:2VB
Average EV/EBITDA: 437.3
Negative Multiple: -16.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.9
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.7
9%
1.7
CH
Roche Holding AG
SIX:ROG
11.3
4%
2.8
UK
AstraZeneca PLC
LSE:AZN
108
10%
10.8
CH
Novartis AG
SIX:NOVN
11.1
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.1
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
P
Provention Bio Inc
F:2VB
Average EV/EBIT: 1 878.2
Negative Multiple: -16.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.4
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.4
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.2
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
158.1
23%
6.9
CH
Novartis AG
SIX:NOVN
14.4
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.7
8%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
10.5
1%
10.5
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
8%
1.3